Abstract | OBJECTIVE: STUDY DESIGN: In a randomized trial, 57 patients and 57 controls with recurrent vulvovaginal candidiasis were assigned either to receive one-day monthly itraconazole prophylaxis for six months or no treatment. Clinical and mycologic evaluations were carried out 3, 6 and 12 months after enrollment. RESULTS: During the first six months of follow-up, the rate of symptomatic recurrences was 36.4% (20/55) among the treated women and 64.2% (34/53) in the controls. The mean time +/- SEM to symptomatic recurrence was 149 +/- 6 days among patients receiving prophylaxis and 120 +/- 6 days in the controls (P = .003 by log-rank test). These differences disappeared almost completely after the cessation of intermittent prophylaxis. In fact, the proportion of patients still asymptomatic after one year of follow-up was 38.9% (21/54) among treated women and 28.8% (15/53) in the controls (P = .83 by Fisher's exact test). CONCLUSION: One-day monthly, intermittent itraconazole prophylaxis reduced the rate of recurrence in patients with recurrent vulvovaginal candidiasis, but the beneficial effect of itraconazole was lost within a few months after cessation of prophylaxis.
|
Authors | A Spinillo, L Colonna, G Piazzi, F Baltaro, A Monaco, A Ferrari |
Journal | The Journal of reproductive medicine
(J Reprod Med)
Vol. 42
Issue 2
Pg. 83-7
(Feb 1997)
ISSN: 0024-7758 [Print] United States |
PMID | 9058342
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antifungal Agents
- Itraconazole
|
Topics |
- Adult
- Antifungal Agents
(administration & dosage, therapeutic use)
- Candidiasis, Vulvovaginal
(drug therapy, prevention & control)
- Female
- Humans
- Itraconazole
(administration & dosage, therapeutic use)
- Recurrence
|